Clinical Trials Browser

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03035331 2026-05-04

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Phase 1/2 Completed

11 enrolled 12 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05507541 2026-04-22

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

10 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

53 enrolled 10 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03990961 2026-02-20

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Terminated

5 enrolled 11 charts

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05179603 2025-12-24

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Phase 2 Terminated

14 enrolled 15 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03150329 2025-09-03

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Phase 1 Active not recruiting

52 enrolled 13 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Phase 2 Terminated

18 enrolled 14 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Phase 2 Active not recruiting

51 enrolled

Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03340766 2024-10-17

HARBOUR

Phase 1 Completed

31 enrolled 29 charts

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Phase 1 Completed

132 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

NCT03255018 2023-11-28

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Phase 2 Completed

12 enrolled 21 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03309878 2023-09-21

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Phase 1/2 Completed

8 enrolled 10 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

159 enrolled

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT04920617 2023-04-07

VITALIZE

Phase 2 Recruiting

102 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03630159 2022-08-15

PORTIA

Phase 1 Completed

12 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03873025 2021-08-17

PLACARD

Phase 1/2 Withdrawn

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01953692 2021-08-04

MK-3475-013

Phase 1 Completed

197 enrolled 52 charts

LymphoidMyeloidPlasma cell

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Large B-Cell, Diffuse

NCT02541565 2020-10-14

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Phase 1 Completed

30 enrolled 9 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Composite Lymphoma

NCT04279938 2020-02-21

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Phase 1 Withdrawn

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02950220 2019-07-30

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1 Completed

2 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell